الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 110 |  |  |
| | | from | 110 | | |
Abstract
CP/CPPS is considered one of the most common urological problems that affects large number of patients. It could be featured by different symptoms, lasting and fluctuating over the time, such as genitourinary and pelvic pain, voiding and storage symptoms and sometimes sexual dysfunction leading to affecting the quality of their life. Due to the still elusive pathophysiology of CP/CPPS, the establishment of effective treatment modalities remains challenging. A wide variety of pharmacologic and non-pharmacologic therapies have been studied such as alpha blockers, antibiotic therapy and anti-inflammatories and pelvic floor physiotherapy. Aim of the work: To assess the efficacy and safety of PDE-5 inhibitor; Tadalafil for treatment of CP/CPP versus combined tamsulosin and ciprofloxacin. Patients and Methods: It is a prospective randomized controlled single blinded phase III clinical trial that was carried out at outpatient clinic in Urology and Nephrology Center, Mansoura University. Between May 2020 and April 2022, 97 patients with a diagnosis of type IIIa chronic non-bacterial prostatitis according to EUA guideline were enrolled in the final analysis at the end of study. Forty-nine for tadalafil (group A), who received tadalafil 5 mg once daily before bed time for 12 weeks and forty-eight for combined tamsulosin and ciprofloxacin (group B) who received ciprofloxacin 1000 mg once daily PO after meal and tamsulosin 0.4 mg before bed time for the same period. Patients were followed for 12 weeks after administration of treatment. Results : Patients baseline characteristics were comparable in both groups. At the end of RCT, tadalafil-group patients showed significant improvement in total, pain, urinary and Qol domains of NIH-CPSI compared to baseline. When compared to combined tamsulosin and ciprofloxacin, all 12th week NIH-CPSI domains scores, except for urinary, were significantly better in tadalafil group. Although, tadalafil-group patients showed significant improvement sexual function assessed with IIEF-15 in comparison with pre-treatment score, while for combination group it showed no difference in comparison with basal level. Conclusion: Tadalafil is effective and safe treatment modality for CP/CPPS. It has the advantage of giving more pain relief and improvement of sexual function compared with combined tamsulosin and ciprofloxacin. Recommendations: To study CP/CPPS, and further studies should be encouraged to confirm the results obtained in our study.